Pear Therapeutics Total Revenue

The latest total revenue for PEAR is $13M as of December 2022. That compares with $4.2M in the prior-year period — up 201.7% year over year. That is below the sector sector average of $1.3B. Investors often review this figure alongside Pear Therapeutics's historical trend and sector peers before judging valuation or financial health.

Over the past year, PEAR's total revenue moved from $4.2M to $13M — a 201.7% year-over-year increase. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Pear Therapeutics's operating scale or balance-sheet position.

Against its sector companies, PEAR currently prints $13M for total revenue, while the sector average sits near $1.3B. That is roughly 99.0% below the sector mean. Large gaps often invite a closer look at Pear Therapeutics's growth, margins, and balance sheet.

A total revenue figure of $13M for PEAR is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. The sector average is about $1.3B. Explore the charts below for those layers of context.

After noting PEAR's total revenue ($13M), review year-over-year change from $4.2M, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.